Search Cytomegalovirus in Healthy Volunteers Stools Samples Selected as Potential Donor for Fecal Microbiota Transplant

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-06-30

Study Completion Date

2017-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Fecal microbiota transplantation (FMT) is recommended in the treatment of recurrent Clostridium difficile infection (CDI). The principle is to administer a fecal suspension of a healthy subject (donor) in the digestive tract of a patient with an CDI (receiver). Donors are being clinical and laboratory screening to reduce the likelihood of pathogens transmission (infectious and other). Cytomegalovirus (CMV) is part of the examinations requested by the Agence national de sécurité du médicament et des produits de santé in the context of clinical research. A sero-matching between donor and recipient CMV is requested. This recommendation eliminates many potential donors to a recipient. To date, the frequency detection level of CMV in stool in healthy volunteers with documented positive CMV serology is not known. In addition, CMV transmission risk via the stool is not established. This study aims to determine the detection frequency of CMV in healthy volunteers stool samples selected as potential donors for a FMT and having a positive CMV serology documented

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Changes in Recipients Gut Microbiota After Fecal Microbiota Transplantation

NCT05739825

Clostridioides Difficile Infection Recurrence

RECRUITING

Multicentre Blinded Comparison of Lyophilized Sterile Fecal Filtrate to Lyophilized Fecal Microbiota Transplant in Recurrent Clostridioides Difficile Infection

NCT03806803

Clostridia Difficile Colitis Clostridium Difficile Diarrhea

COMPLETED PHASE2

Fecal Microbiota Transplant (FMT) for Relapsing C. Difficile Infection in Adults and Children Using a Frozen Inoculum

NCT01704937

Clostridium Difficile Infection

COMPLETED PHASE1

The Dynamic Fluctuation of Donor Microbiota Affects the Prognosis of Fecal Microbiota Transplantation for C. Difficile Infection

NCT05703477

Clostridium Difficile Infection Fecal Microbiota Transplantation

COMPLETED NA

Profiling Fecal Samples for Selection of Donors of Feces

NCT04078581

Fecal Microbiota Transplantation

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

CMV Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy volunteers

For healthy volunteers corresponding to the inclusion criteria it will be taken them Blood and stool samples : a blood sample during the inclusion visit and if they are seropositive for the CMV, it will be taken them another blood sample and they will give a stool sample for the following visit

Group Type OTHER

Blood and stool samples

Intervention Type OTHER

Blood sample at Day 1 and blood and stool sample at the next visit

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood and stool samples

Blood sample at Day 1 and blood and stool sample at the next visit

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged over 18 and under 65 years
* Having a normal transit (less than three stools per day and more than three bowel movements per week)
* Body mass index (BMI) \<30 and\> 16.9
* Accept the constraints of the study, ie two visits (inclusion and Following Visit), a stool sample, two blood tests
* Having given and signed informed consent
* Being affiliated or beneficiary of a social security scheme

Exclusion Criteria

* Taking a treatment with anti-CMV action in three months by acyclovir, valacyclovir, ganciclovir, valganciclovir, foscarnet, cidofovir, brincidofovir
* Digestive disorders (acute or chronic diarrhea) in the three months prior to donation
* Known chronic disease (except hypertension and hypercholesterolemia)
* Documented history of typhoid fever
* Taking long-term medication (except contraceptives, cholesterol-lowering and antihypertensive treatment)
* Antibiotic taken within three months
* Stay in tropics during the three months prior to donation,
* Residence of several years in tropics (over 24 months)
* Hospitalization abroad of more than 24 hours in the last 12 months to the donor or his entourage (those living under the same roof)
* Healthy Volunteers who have not reached the limit of compensation by social security or exclusion period

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes